These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 39248564)
1. Diverse BCR usage and T cell activation induced by different COVID-19 sequential vaccinations. Wang J; Li K; Wang Y; Lin Z; Li W; Cao J; Mei X; Wei R; Yang J; Zhai X; Huang D; Zhou K; Liang X; Wang Z mBio; 2024 Oct; 15(10):e0142924. PubMed ID: 39248564 [TBL] [Abstract][Full Text] [Related]
2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
3. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain. Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250 [TBL] [Abstract][Full Text] [Related]
4. T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. Koutsakos M; Lee WS; Wheatley AK; Kent SJ; Juno JA J Leukoc Biol; 2022 Feb; 111(2):355-365. PubMed ID: 34730247 [TBL] [Abstract][Full Text] [Related]
5. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM Front Immunol; 2021; 12():742914. PubMed ID: 34659237 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH; Front Immunol; 2024; 15():1390022. PubMed ID: 38698851 [TBL] [Abstract][Full Text] [Related]
7. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087 [TBL] [Abstract][Full Text] [Related]
8. mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells. Liu S; van Dijk LLA; den Hartog Y; Hoek R; Verschuuren E; Geurtsvankessel CH; de Vries RD; Van Baarle D; Buter CVL Vaccine; 2024 Oct; 42(24):126250. PubMed ID: 39226789 [TBL] [Abstract][Full Text] [Related]
9. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters. Zhang XS; Windau A; Meyers J; Yang X; Dong F Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540 [TBL] [Abstract][Full Text] [Related]
11. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM Front Immunol; 2021; 12():747830. PubMed ID: 34858404 [TBL] [Abstract][Full Text] [Related]
12. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
13. Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. Komissarov AA; Dolzhikova IV; Efimov GA; Logunov DY; Mityaeva O; Molodtsov IA; Naigovzina NB; Peshkova IO; Shcheblyakov DV; Volchkov P; Gintsburg AL; Vasilieva E J Immunol; 2022 Mar; 208(5):1139-1145. PubMed ID: 35101893 [TBL] [Abstract][Full Text] [Related]
14. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV. Lv Z; Lv S; Li Q; Xia Y; Feng Z; Zhang H; Yang H; Wu Z; Zou N; Mo Q; Gu Q; Ying S; Wang X; Qin D; Wan C Front Immunol; 2023; 14():1264160. PubMed ID: 38045691 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048 [TBL] [Abstract][Full Text] [Related]
17. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778 [TBL] [Abstract][Full Text] [Related]